AIT Investments says that it is actively pursuing a possible all-cash offer for UK-based pharmaceutical and consumer health company Goldshield Group, in conjunction with Ajit Patel, the former chief executive of Goldshield.
AIT is completing its due diligence and expects to clarify its position shortly. A further announcement will be made when appropriate, it said.
Commenting recently on the firm's half-year results, Rakesh Patel, chief executive was upbeat about the company's performance, noting that pretax profits had increased 71.8%, revenue was up 15.9% and cash reserves have grown to £27.5 million ($44 million). 'I fully intend to use our resources to invest in new product introductions via development, in-licensing and acquisitions together with the scaling and building of our brands. Sustainable long-term growth is an area at the forefront of our objectives. We are entering an exciting period for Goldshield and I am confident that we can continue to drive value for our shareholders," he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze